Sophie Erhardt
About me
Dr. Sophie Erhardt is Professor in Experimental Psychiatry and research group leader for Neuropsychoimmunology [1] at the Department of Physiology and Pharmacology. She is also Head of the Dept of Physiology and Pharmacology (FyFa). Fyfa, conducts internationally recognized research and education in physiology, pharmacology, anaesthesiology and intensive care. In addition to her role at FyFa, Sophie represents KI in Karolinska University Hospital’s comprehensive resource for anesthesia, surgery, pre- and post-operative care, and adult intensive care. She also serves as the Academic Coordinator for the collaborative platform between KI and Mayo Clinic, USA, and is a member of its steering board.
Sophie holds several leadership positions in scientific organizations. She is the President of the Scandinavian College of Neuropsychopharmacology and President-Elect of the International Society of Tryptophan Research. Additionally, she is a steering board member for Comparative Medicine and the Karolinska Schizophrenia Project at KI. She also serves as Secretary of the Royal Swedish Academy of Sciences’ National Committee for Pharmacology, Physiology, and Neuroscience.
Sophie earned her doctoral degree in pharmacology at KI in 2001, focusing on glutamatergic regulation of dopaminergic signaling. In 2002, she completed her postdoctoral training at the University of California San Diego, USA. Upon returning to KI, she established the Neuropsychoimmunology group, became an Associated Professor in 2006, and was appointed Professor in 2016. Since 2022, she has served as Head of Department of Physiology and Pharmacology.
Dr. Sophie Erhardt was awarded the Maltz Prize for Innovative & Promising Schizophrenia Research from the American Brain & Behavior Research Foundation in 2022 and the Arvid Carlsson Award for young scientists in 2023. Sophie is the Head of Dept of Physiology and Pharmacology at KI, the Academic Coordinator for the KI-Mayo Clinic collaboration, the President of the SCNP (Scandinavian College of Neuropsychopharmacology), and the President-Elect of the ISTRY (International Society of Tryptophan Research).
Throughout her career, Sophie has authored more than 140 scientific articles and has supervised 16 doctoral students through their thesis defenses, including 10 as main supervisor. She continues to lead the Neuropsychoimmunology group, which now consists of 19 researchers.
Research
My research focuses on the kynurenine pathway and its critical role in the pathophysiology of psychiatric disorders, particularly schizophrenia and cognitive dysfunction. Over the past 25 years, I have contributed to fundamental discoveries that have reshaped our understanding of how immune activation influences brain function through metabolites such as kynurenic acid (KYNA).
A key breakthrough in my work was identifying that KAT III, rather than KAT II, is the primary enzyme responsible for KYNA synthesis during immune activation. This finding has opened new therapeutic avenues, leading to the development of novel KAT III inhibitors currently in advanced stages of drug discovery. These inhibitors hold promise for treating immune-induced psychosis and cognitive decline, representing a next-generation strategy in neuropsychiatric drug development.
In parallel, my research explores biomarkers like picolinic acid (PIC), which may serve as predictive tools for suicide risk and early intervention. By integrating experimental neuroscience, clinical psychiatry, and drug development, my lab aims to bridge the gap between basic research and precision medicine. We focus on identifying biomarkers that enable early diagnosis, guide treatment decisions, and monitor therapeutic responses, thereby optimizing clinical outcomes.
Our multidisciplinary approach combines advanced technologies and cross-sector collaborations, spanning psychiatry, neurology, immunology, pharmacology, and bioinformatics. This synergy fosters innovative strategies to understand and treat psychotic disorders and cognitive impairments, with the ultimate goal of improving patient care.
Recognized internationally, my work has been honored with awards such as the Arvid Carlsson Prize and the Maltz Prize for Innovative Schizophrenia Research. Supported by SciLifeLab’s Drug Discovery and Development platform, our ongoing projects continue to push the boundaries of neuropsychopharmacology and biomarker research.
Teaching
I have over 25 years of experience teaching pharmacology at both undergraduate and graduate levels, with a particular focus on medical and biomedical education. My teaching expertise covers a wide range of topics, including neuropsychopharmacology, cardiovascular pharmacology, and the pharmacology of immune and inflammatory systems.
I have served as course coordinator for the “Single Subject Course in Pharmacology” (15 credits) at the Department of Physiology & Pharmacology, Karolinska Institutet, for ten years. In this role, I was responsible for course planning, student admissions, curriculum development, examination, and course evaluation.
Currently, I am responsible for the pharmacology content in modules 1, 3, and 4 of BV4 in semester 2 of the medical program at Karolinska Institutet (läkarlinjen). I also contribute to a variety of courses organized by the Department of Physiology & Pharmacology, including courses in the Medical Informatics, Biomedicine, and Optometry programs.
My teaching activities include lectures, group seminars, laboratory supervision, case-based learning, and examination design. I have extensive experience in supervising laboratory exercises and leading group discussions, as well as evaluating both oral and written examinations. My commitment to high-quality education is reflected in consistently positive student evaluations and active involvement in curriculum development.
In summary, my teaching philosophy is grounded in fostering an engaging and inclusive learning environment, promoting critical thinking, and integrating the latest research advances into my teaching.
Articles
- Journal article: BIOLOGICAL PSYCHIATRY. 2025;97(9):s133
- Article: AMERICAN JOURNAL OF PSYCHIATRY. 2025;182(4):389-400
- Article: BRAIN BEHAVIOR AND IMMUNITY. 2025;125:452-465
- Article: BRAIN BEHAVIOR AND IMMUNITY. 2025;124:163-176
- Article: PLOS ONE. 2025;20(1):e0317201
- Journal article: PHARMACOLOGICAL REVIEWS. 2024;76(6):978-1008
- Article: MEDICINE & SCIENCE IN SPORTS & EXERCISE. 2024;56(10):2007-2015
- Journal article: EUROPEAN JOURNAL OF CLINICAL NUTRITION. 2024;78(8):677-683
- Article: BRAIN BEHAVIOR AND IMMUNITY. 2024;117:313-319
- Article: JOURNAL OF PSYCHIATRIC RESEARCH. 2024;171:306-315
- Journal article: INTERNATIONAL JOURNAL OF TRYPTOPHAN RESEARCH. 2024;17:11786469241262876
- Article: PSYCHIATRY AND CLINICAL NEUROSCIENCES. 2023;77(12):665-671
- Article: ACTA NEUROPSYCHIATRICA. 2023;37:1-13
- Article: BRAIN BEHAVIOR AND IMMUNITY. 2023;111:376-385
- Article: PSYCHONEUROENDOCRINOLOGY. 2023;153:106110
- Article: SCHIZOPHRENIA RESEARCH. 2023;257:34-40
- Article: LEUKEMIA. 2023;37(4):888-900
- Journal article: NEUROSCIENCE APPLIED. 2023;2:103551
- Article: NATURE COMMUNICATIONS. 2022;13(1):6427
- Article: INTERNATIONAL JOURNAL OF BIPOLAR DISORDERS. 2022;10(1):26
- Article: HELIYON. 2022;8(9):e10424
- Article: MOLECULAR PSYCHIATRY. 2022;27(8):3247-3261
- Article: BRITISH JOURNAL OF NUTRITION. 2022;129(6):1-8
- Article: TRANSLATIONAL PSYCHIATRY. 2022;12(1):229
- Article: BRAIN BEHAVIOR AND IMMUNITY. 2022;101:136-145
- Article: MOLECULAR PSYCHIATRY. 2022;27(2):1233-1240
- Article: TRANSLATIONAL PSYCHIATRY. 2021;11(1):566
- Article: MOLECULAR PSYCHIATRY. 2021;26(11):6820-6832
- Journal article: BRAIN BEHAVIOR AND IMMUNITY. 2021;98:50
- Article: NPJ SCHIZOPHRENIA. 2021;7(1):46
- Article: SCIENTIFIC REPORTS. 2021;11(1):7527
- Journal article: ACTA NEUROPSYCHIATRICA. 2021;33(2):111-112
- Article: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2021;43:52-62
- Article: SCHIZOPHRENIA RESEARCH. 2021;228:118-123
- Article: SCIENTIFIC REPORTS. 2021;11(1):1669
- Article: FRONTIERS IN PSYCHIATRY. 2021;12:714014
- Article: INTERNATIONAL JOURNAL OF TRYPTOPHAN RESEARCH. 2021;14:11786469211041368
- Article: JOURNAL OF NEUROIMMUNOLOGY. 2020;349:577401
- Article: BIOLOGICAL PSYCHIATRY-COGNITIVE NEUROSCIENCE AND NEUROIMAGING. 2020;5(12):1095-1103
- Article: EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE. 2020;270(7):933-938
- Article: NATURE COMMUNICATIONS. 2020;11(1):4016
- Article: ACS CHEMICAL NEUROSCIENCE. 2020;11(12):1756-1761
- Article: IBRO REPORTS. 2020;8:136-142
- Article: BIOANALYSIS. 2020;12(6):379-392
- Article: ACTA NEUROPSYCHIATRICA. 2020;32(1):43-53
- Article: INTERNATIONAL JOURNAL OF TRYPTOPHAN RESEARCH. 2020;13:1178646920978241
- Article: PSYCHIATRY RESEARCH. 2019;281:112546
- Article: NATURE NEUROSCIENCE. 2019;22(10):1617-1623
- Article: SCHIZOPHRENIA RESEARCH. 2019;210:221-227
- Article: JAMA PSYCHIATRY. 2019;76(7):739-748
- Article: TRANSLATIONAL PSYCHIATRY. 2019;9(1):37
- Article: TRANSLATIONAL PSYCHIATRY. 2019;9(1):12
- Article: INTERNATIONAL JOURNAL OF TRYPTOPHAN RESEARCH. 2019;12:1178646919891169
- Article: ACTA PSYCHIATRICA SCANDINAVICA. 2018;138(5):432-440
- Article: BIOLOGICAL PSYCHIATRY. 2018;84(9):644-654
- Article: NEUROPHARMACOLOGY. 2018;138:130-139
- Article: MOLECULAR PSYCHIATRY. 2018;23(5):1244-1250
- Article: PSYCHOLOGICAL MEDICINE. 2018;48(1):82-94
- Article: JOURNAL OF NEUROIMMUNOLOGY. 2017;313:1-9
- Article: BIOLOGICAL PSYCHIATRY. 2017;82(10):756-765
- Article: MOLECULAR PSYCHIATRY. 2017;22(6):850-856
- Article: ACTA PSYCHIATRICA SCANDINAVICA. 2017;135(5):439-447
- Article: NEUROPSYCHIATRIC DISEASE AND TREATMENT. 2017;13:967-972
- Article: ACTA NEUROPSYCHIATRICA. 2017;29(1):54-58
- Article: PSYCHIATRY RESEARCH. 2017;247:105-112
- Article: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 2016;84(5):262-271
- Article: DIABETES-METABOLISM RESEARCH AND REVIEWS. 2016;32(7):754-761
- Article: MOLECULAR PSYCHIATRY. 2016;21(10):1342-1350
- Article: NEUROCHEMICAL RESEARCH. 2016;41(9):2243-2255
- Article: PSYCHONEUROENDOCRINOLOGY. 2016;71:189-196
- Article: TRANSLATIONAL PSYCHIATRY. 2016;6(8):e865
- Article: FEBS LETTERS. 2016;590(14):2063-2075
- Article: AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY. 2016;310(10):C836-C840
- Article: JOURNAL OF AFFECTIVE DISORDERS. 2016;193:349-354
- Article: NEUROPHARMACOLOGY. 2016;102:42-47
- Article: JOURNAL OF NEUROINFLAMMATION. 2016;13(1):51
- Article: BRAIN BEHAVIOR AND IMMUNITY. 2016;51:47-55
- Article: ACTA PSYCHIATRICA SCANDINAVICA. 2015;131(4):269-278
- Article: JOURNAL OF PSYCHIATRY & NEUROSCIENCE. 2015;40(2):126-133
- Article: INTERNATIONAL JOURNAL OF TRYPTOPHAN RESEARCH. 2015;8:49-52
- Article: BRAIN BEHAVIOR AND IMMUNITY. 2015;43:110-117
- Article: CELL. 2014;159(1):33-45
- Article: MOLECULAR PSYCHIATRY. 2014;19(3):334-341
- Article: BRAIN BEHAVIOR AND IMMUNITY. 2014;36:80-89
- Article: INTERNATIONAL JOURNAL OF TRYPTOPHAN RESEARCH. 2014;7:15-22
- Article: INTERNATIONAL JOURNAL OF TRYPTOPHAN RESEARCH. 2014;7:1-7
- Journal article: INTERNATIONAL JOURNAL OF TRYPTOPHAN RESEARCH. 2014;7:1-7
- Journal article: INTERNATIONAL JOURNAL OF TRYPTOPHAN RESEARCH. 2014;7:15-22
- Article: PSYCHONEUROENDOCRINOLOGY. 2013;38(6):853-862
- Article: NEUROPSYCHOPHARMACOLOGY. 2013;38(5):743-752
- Article: PSYCHIATRY RESEARCH. 2013;205(1-2):165-167
- Journal article: INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY. 2012;28(&NA;):e4
- Journal article: INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY. 2012;28(&NA;):e25
- Journal article: INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY. 2012;28(&NA;):e42
- Journal article: INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY. 2012;28(&NA;):e41-e42
- Article: BIPOLAR DISORDERS. 2012;14(7):719-726
- Article: SCHIZOPHRENIA BULLETIN. 2012;38(3):426-432
- Journal article: NEUROLOGY PSYCHIATRY AND BRAIN RESEARCH. 2012;18(2):62
- Article: JOURNAL OF NEURAL TRANSMISSION. 2012;119(2):155-163
- Article: JOURNAL OF PSYCHIATRY & NEUROSCIENCE. 2012;37(1):53-57
- Article: ACTA PSYCHIATRICA SCANDINAVICA. 2011;124(1):52-61
- Article: JOURNAL OF PSYCHIATRY & NEUROSCIENCE. 2011;36(2):114-118
- Article: JOURNAL OF NEUROINFLAMMATION. 2010;7:44
- Article: JOURNAL OF PSYCHIATRY & NEUROSCIENCE. 2010;35(3):195-199
- Article: INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY. 2010;13(4):475-485
- Article: INTERNATIONAL JOURNAL OF TRYPTOPHAN RESEARCH. 2010;3:1-12
- Article: BIOLOGICAL PSYCHIATRY. 2009;66(3):287-292
- Article: INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY. 2009;12(4):501-512
- Article: ENDOCRINOLOGY. 2008;149(12):6356-6365
- Article: LIFE SCIENCES. 2008;83(5-6):170-175
- Journal article: SCHIZOPHRENIA RESEARCH. 2008;102(1-3):94
- Journal article: JOURNAL OF PROTEOMICS AND BIOINFORMATICS. 2008;01(02):090-097
- Article: NEUROPHARMACOLOGY. 2007;53(8):918-924
- Article: PHYSIOLOGY & BEHAVIOR. 2007;92(1-2):203-209
- Article: ACTA NEUROPSYCHIATRICA. 2007;19(1):45-52
- Article: JOURNAL OF PSYCHIATRIC RESEARCH. 2007;41(1-2):144-151
- Article: JOURNAL OF NEURAL TRANSMISSION. 2006;113(5):557-571
- Article: SYNAPSE-STRUCTURE FUNCTION CONNECTIVITY. 2006;59(5):290-298
- Article: SCHIZOPHRENIA RESEARCH. 2005;80(2-3):315-322
- Article: INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY. 2005;8(3):329-339
- Article: JOURNAL OF NEURAL TRANSMISSION. 2005;112(7):863-872
- Article: BIOLOGICAL PSYCHIATRY. 2004;56(4):255-260
- Article: SYNAPSE-STRUCTURE FUNCTION CONNECTIVITY. 2004;52(2):114-122
- Article: NEUROPSYCHOPHARMACOLOGY. 2003;28(10):1770-1777
- Article: LIFE SCIENCES. 2003;72(24):2793-2801
- Article: ACTA PHYSIOLOGICA. 2002;175(1):45-53
- Article: SYNAPSE-STRUCTURE FUNCTION CONNECTIVITY. 2002;43(4):227-237
- Article: NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY. 2002;365(3):173-180
- Article: NEUROSCIENCE LETTERS. 2001;313(1-2):96-98
- Article: AMINO ACIDS. 2001;20(4):353-362
- Article: NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY. 2001;363(1):21-27
- Article: LIFE SCIENCES. 2000;67(15):1901-1911
- Article: SYNAPSE-STRUCTURE FUNCTION CONNECTIVITY. 2000;37(2):104-108
- Article: NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY. 2000;362(1):41-45
- Article: JOURNAL OF NEURAL TRANSMISSION. 1999;106(5-6):383-394
- Article: NEUROSCIENCE LETTERS. 1998;255(2):115-118
- Article: NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY. 1998;357(6):611-619
- Show more
All other publications
- Review: JAMA PSYCHIATRY. 2024;81(5):468-476
- Editorial comment: NEUROPSYCHOPHARMACOLOGY. 2024;49(1):307-308
- Conference publication: NEUROPSYCHOPHARMACOLOGY. 2024;49:400-401
- Letter: BRAIN BEHAVIOR AND IMMUNITY. 2023;114:163-164
- Preprint: BIORXIV. 2023
- Conference publication: BIOLOGICAL PSYCHIATRY. 2023;93(9):S24
- Conference publication: BIOLOGICAL PSYCHIATRY. 2023;93(9):S24
- Review: BRAIN SCIENCES. 2023;13(3):505
- Conference publication: NEUROPSYCHOPHARMACOLOGY. 2023;48:356-357
- Corrigendum: MOLECULAR PSYCHIATRY. 2022;27(3):1855
- Conference publication: NEUROPSYCHOPHARMACOLOGY. 2022;47:378-379
- Conference publication: NEUROPSYCHOPHARMACOLOGY. 2022;47:277
- Conference publication: NEUROPSYCHOPHARMACOLOGY. 2022;47:290-291
- Letter: SCHIZOPHRENIA RESEARCH. 2019;208:490-492
- Letter: BIOLOGICAL PSYCHIATRY. 2019;85(7):e35-e39
- Conference publication: NEUROPSYCHOPHARMACOLOGY. 2019;44(SUPPL 1):490-491
- Conference publication: NEUROPSYCHOPHARMACOLOGY. 2019;44(SUPPL 1):169-170
- Letter: SCHIZOPHRENIA RESEARCH. 2018;199:438-441
- Review: NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS. 2018;90:212-220
- Letter: SCHIZOPHRENIA RESEARCH. 2018;195:406-408
- Meeting abstract: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2017;27:S722
- Conference publication: BIOLOGICAL PSYCHIATRY. 2017;81(10):S266-S267
- Review: NEUROPHARMACOLOGY. 2017;112(Pt B):297-306
- Conference publication: NEUROPSYCHOPHARMACOLOGY. 2017;42:S220-S221
- Conference publication: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 2017;44:S522
- Conference publication: JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM. 2017;37:234
- Conference publication: BIOLOGICAL PSYCHIATRY. 2016;79(9):338S-339S
- Review: LAKARTIDNINGEN. 2015;112:DH34
- Review: ACTA PSYCHIATRICA SCANDINAVICA. 2015;132(3):192-203
- Conference publication: CANCER RESEARCH. 2015;75:1162
- Meeting abstract: EUROPEAN PSYCHIATRY. 2015;30:277
- Conference publication: DIABETOLOGIA. 2015;58:S300
- Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2015;21:351-352
- Corrigendum: CELL. 2015;160(1-2):351
- Conference publication: BIPOLAR DISORDERS. 2014;16:65
- Conference publication: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2013;23:S14-S15
- Conference publication: BIOLOGICAL PSYCHIATRY. 2013;73(9):152S
- Conference publication: BIOLOGICAL PSYCHIATRY. 2013;73(9):34S
- Conference publication: INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY. 2012;15:117
- Conference publication: INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY. 2012;15:128-129
- Conference publication: INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY. 2012;15:134
- Conference publication: INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY. 2012;15:128
- Conference publication: INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY. 2012;15:228
- Conference publication: INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY. 2012;15:180
- Conference publication: INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY. 2012;15:179
- Conference publication: INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY. 2012;15:28
- Letter: SCHIZOPHRENIA RESEARCH. 2011;127(1-3):270-272
- Conference publication: BIPOLAR DISORDERS. 2011;13:87
- Meeting abstract: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2010;20:S40
- Letter: MOLECULAR PSYCHIATRY. 2009;14(12):1069-1071
- Meeting abstract: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2009;19:S178
- Review: CNS DRUGS. 2009;23(2):91-101
- Conference publication: INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY. 2008;11:180
- Meeting abstract: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2007;17:S422-S423
- Meeting abstract: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2007;17:S419-S420
- Meeting abstract: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2007;17:S219
- Meeting abstract: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2007;17:S264-S265
- Meeting abstract: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2006;16:S435-S436
- Meeting abstract: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2006;16:S377
- Conference publication: NEUROPSYCHOPHARMACOLOGY. 2006;31:S126
- Conference publication: NEUROPSYCHOPHARMACOLOGY. 2006;31:S45
- Conference publication: NORDIC JOURNAL OF PSYCHIATRY. 2006;60(4):334
- Conference publication: NORDIC JOURNAL OF PSYCHIATRY. 2006;60(4):328-329
- Conference publication: NORDIC JOURNAL OF PSYCHIATRY. 2006;60(4):321
- Conference publication: NEUROPSYCHOPHARMACOLOGY. 2006;31:S45-S46
- Meeting abstract: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2005;15:S34-S35
- Conference publication: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2005;15:S320
- Conference publication: NORDIC JOURNAL OF PSYCHIATRY. 2005;59(5):416-417
- Conference publication: NORDIC JOURNAL OF PSYCHIATRY. 2005;59(5):414
- Conference publication: NORDIC JOURNAL OF PSYCHIATRY. 2005;59(5):409
- Conference publication: NORDIC JOURNAL OF PSYCHIATRY. 2004;58(2):94
- Conference publication: NORDIC JOURNAL OF PSYCHIATRY. 2004;58(2):106-107
- Conference publication: NORDIC JOURNAL OF PSYCHIATRY. 2004;58(2):102
- Published conference paper: CELL BIOLOGY AND TRANSLATIONAL MEDICINE, VOL 14: STEM CELLS IN LINEAGE SPECIFIC DIFFERENTIATION AND DISEASE. 2003;527:155-165
- Conference publication: NORDIC JOURNAL OF PSYCHIATRY. 2001;55(2):90
- Conference publication: NORDIC JOURNAL OF PSYCHIATRY. 2001;55(2):89
- Conference publication: NORDIC JOURNAL OF PSYCHIATRY. 2000;54(2):93
- Conference publication: NORDIC JOURNAL OF PSYCHIATRY. 1999;53(2):110
- Conference publication: NORDIC JOURNAL OF PSYCHIATRY. 1998;52(2):135
- Show more
Grants
- Swedish Research Council1 January 2025 - 31 December 2027
- Swedish Research Council1 January 2022 - 31 December 2024
- Swedish Research Council1 January 2022 - 31 December 2024
- Generation of enzyme inhibitors for the treatment of immune-induced psychosis and cognitive deficitsNovo Nordisk Foundation1 August 2021 - 31 July 2022
- Swedish Research Council1 January 2020 - 31 December 2023
- Swedish Research Council1 November 2019 - 30 November 2019
- Swedish Research Council1 January 2018 - 31 December 2021
- Swedish Research Council1 January 2018 - 31 December 2020
- Swedish Research Council1 January 2017 - 31 December 2019
- Swedish Research Council1 January 2014 - 31 December 2017
- Swedish Research Council1 January 2012 - 31 December 2013
- Swedish Research Council1 January 2012 - 31 December 2013
- Swedish Research Council1 September 2010 - 31 August 2016
- Swedish Research Council1 September 2010 - 31 August 2016
- Swedish Research Council1 January 2010 - 31 December 2011
Employments
- Professor, Department of Physiology and Pharmacology, Karolinska Institutet, 2016-
Degrees and Education
- Docent, Karolinska Institutet, 2006
- Doctor Of Philosophy, Department of Physiology and Pharmacology, Karolinska Institutet, 2001
Leadership and responsibility assignments
- Head of department, Department of Physiology and Pharmacology, Karolinska Institutet, 2022-